Europe Vaccine Adjuvants Market Forecast to 2030 – Regional Analysis – by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
The Europe vaccine adjuvants market was valued at US$ 740.50 million in 2022 and is expected to reach US$ 2,051.05 million by 2030; it is estimated to register a CAGR of 13.6% from 2022 to 2030.
Approvals of Veterinary Vaccine Adjuvants Drive Europe Vaccine Adjuvants Market
Vaccinating animals against common diseases remains the most successful method worldwide to prevent financial and other losses from infectious diseases in animal farming. Regulatory approvals for veterinary vaccine adjuvants are increasing, with manufacturers' growing focus on developing vaccines with greater efficacy and stability. Montanide is one of the known veterinary vaccine adjuvants. The Montanide adjuvant range is based on three core technologies—emulsions, micro-emulsions, and polymers. Therefore, an upsurge in adjuvant approvals for veterinary vaccines accelerates the overall market growth of vaccine adjuvants.
Europe Vaccine Adjuvants Market Overview
The Europe vaccine adjuvant market has been segmented into Germany, UK, France, Italy, Spain, and the Rest of Europe. A few top vaccine manufacturers have a presence in Germany. In December 2022, Evonik launched a plant-based squalene named PhytoSquene to improve vaccine efficacy. It is a non-animal derivative suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene introduced in the market for adjuvants in drugs indicated for parenteral usage. This latest innovation of Evonik is meant to provide the market with sustainable, non-animal derivative solutions. In 2021, Evonik launched the pharma-grade and plant-derived cholesterol “PhytoChol".
Europe Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
Get more information on this report :
Europe Vaccine Adjuvants Market Segmentation
The Europe vaccine adjuvants market is categorized into adjuvant class, type, and country.
Based on adjuvant class, the Europe vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Europe vaccine adjuvants market share in 2022.
By type, the Europe vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Europe vaccine adjuvants market in 2022.
By country, the Europe vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe vaccine adjuvants market share in 2022.
Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; InvivoGen SAS; Novavax Inc.; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the Europe vaccine adjuvants market.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Vaccine Adjuvants Market – Key Market Dynamics
4.1 Europe Vaccine Adjuvants Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunities
4.4.1 Advancements in Biotechnology and Immunology
4.5 Future Trends
4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:
5. Vaccine Adjuvants Market –Europe Market Analysis
5.1 Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
5.2 Europe Vaccine Adjuvants Market Forecast and Analysis
6. Europe Vaccine Adjuvants Market Analysis – by Adjuvant Class
6.1 Overview
6.2 Mineral Salt Adjuvant
6.2.1 Overview
6.2.2 Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
6.3.1 Overview
6.3.2 Emulsion Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
6.4.1 Overview
6.4.2 Liposome Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. Europe Vaccine Adjuvants Market Analysis – by Type
7.1 Human Vaccine Adjuvant
7.1.1 Overview
7.1.2 Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
7.2.1 Overview
7.2.2 Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Vaccine Adjuvants Market –Country Analysis
8.1 Europe
8.1.1 Europe Vaccine Adjuvants Market
8.1.1.1 Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.1 Overview
8.1.1.1.2 Germany: Glucose Monitoring Devices Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.2 United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.1 Overview
8.1.1.2.2 United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.3 France: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.1 Overview
8.1.1.3.2 France: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.4 Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.1 Overview
8.1.1.4.2 Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.5 Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.5.1 Overview
8.1.1.5.2 Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.6 Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.6.1 Overview
8.1.1.6.2 Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.6.3 Rest of Europe Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.6.4 Rest of Europe Vaccine Adjuvants Market Breakdown, by Type
9. Industry Landscape
9.1 Overview
9.2 Growth Strategies in the Global Vaccine Adjuvants Market
9.3 Organic Developments
9.3.1 Overview
9.4 Inorganic Developments
9.4.1 Overview
10. Company Profiles
10.1 SPI Pharma Inc
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 GSK Plc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 CSL Ltd
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Seppic SA
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Dynavax Technologies Corp
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 InvivoGen SAS
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Croda International Plc
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Novavax Inc
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Phibro Animal Health Corp
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
11. Appendix
11.1 About The Insight Partners
List of Tables
Table 1. Europe Vaccine Adjuvants Market Segmentation
Table 2. Europe Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
Table 3. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 4. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 5. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 6. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 8. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 9. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 10. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 11. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 12. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 13. Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 14. Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 15. Organic Developments Done by Companies
Table 16. Inorganic Developments Done by Companies
List of Figures
Figure 1. Europe Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Vaccine Adjuvants Market Revenue (US$ Million), 2022–2030
Figure 4. Europe Vaccine Adjuvants Market Share (%) – by Adjuvant Class (2022 and 2030)
Figure 5. Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Liposome Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 10. Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Europe Vaccine Adjuvants Market – Revenue by Key Countries Revenue 2022 (US$ Million)
Figure 13. Europe Vaccine Adjuvants Market (2022 and 2030)
Figure 14. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 15. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 16. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 17. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 18. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 19. Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 20. Growth Strategies in the Vaccine Adjuvants Market
- SPI Pharma Inc
- GSK Plc
- CSL Ltd
- Seppic SA
- Dynavax Technologies Corp
- InvivoGen SAS
- Croda International Plc
- Novavax Inc
- Phibro Animal Health Corp
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe vaccine adjuvants market.
- Highlights key business priorities to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.